Align Technology Announces Second Quarter Fiscal 20...(Q2 07(a) U.S. Orthodontists ...),Health
Q2 07(a)
U.S. Orthodontists 4.9 4.8 5.3
U.S. GP Dentists 2.5 2.4 2.7
International 3.3 3.2 3.1
Total Utilization Rate 3.1 3.1 3.4
* Utilization = # of cases/# of doctors to whom cases were shipped
(a) Q2 07 shipments included approximately four thousand cases and revenue
of $5.2 million from the reduction in backlog and cycle times caused
by the allocation of capacity to the Patients First Program during the
fourth quarter of 2006 and the first quarter of 2007
Business Outlook
For the third quarter of fiscal 2008 (Q3 08), Align Technology expects net revenues to be in a range of $74 million to $76 million. GAAP earnings per diluted share for Q3 08 is expected to be in a range of $0.01 to $0.03. Non-GAAP earnings per diluted share for Q3 08 is expected to be in a range of $0.04 to $0.06. Stock-based stock compensation expense for Q3 08 is expected to be approximately $4.7 million.
For fiscal 2008, Align Technology expects net revenues to be in a range of $309 million to $314 million. The increase in deferred revenue for fiscal 2008 is expected to be in the range of $5 million to $8 million primarily associated with new products, which will be recognized in future periods, bringing the Company's total deferred revenue balance at the end of 2008 to a range of $17 million to $20 million. GAAP earnings per diluted share for fiscal 2008 is expected to be in a range of $0.26 to $0.30. Non-GAAP earnings per diluted share for fiscal 2008 is expected to be in a range of $0.29 to $0.33. Stock-based compensation expense for fiscal 2008 is expected to be approximately $17.9 million.
A more comprehensive business outlook is available following the financial tables of this release.
Invisalign Teen
In a sepa
'/>"/>
| SOURCE Align Technology, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Align Technology Executive to Present at Upcoming Financial Conferences
2. WellPoint Announces Realignment of Core Businesses; Names New Executives
3. Align Technology to Announce Third Quarter 2007 Financial Results on October 24, 2007
4. Align Technology, Inc. Earns PACE Approval From Academy of General Dentistry
5. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
6. Threshold Pharmaceuticals Announces Corporate Realignment
7. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
8. Dallas Among the First to Offer Probiotic Supplement Align(R)
9. McGill researchers link enzyme to breast cancer malignancy
10. Breast Cancer Genes Also Raise Mens Risk for Malignancy
11. iNOS expression may links chronic biliary inflammation to malignant transformation
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |